Does APIXABAN Cause Salivary hypersecretion? 22 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 22 reports of Salivary hypersecretion have been filed in association with APIXABAN (ELIQUIS). This represents 0.0% of all adverse event reports for APIXABAN.
22
Reports of Salivary hypersecretion with APIXABAN
0.0%
of all APIXABAN reports
1
Deaths
4
Hospitalizations
How Dangerous Is Salivary hypersecretion From APIXABAN?
Of the 22 reports, 1 (4.5%) resulted in death, 4 (18.2%) required hospitalization.
Is Salivary hypersecretion Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for APIXABAN. However, 22 reports have been filed with the FAERS database.
What Other Side Effects Does APIXABAN Cause?
Death (18,501)
Cerebrovascular accident (7,237)
Atrial fibrillation (5,690)
Off label use (5,590)
Thrombosis (5,298)
Fall (5,063)
Cardiac disorder (4,917)
Haemorrhage (4,770)
Dyspnoea (4,379)
Gastrointestinal haemorrhage (4,030)
What Other Drugs Cause Salivary hypersecretion?
CLOZAPINE (1,349)
ARIPIPRAZOLE (497)
RISPERIDONE (485)
OLANZAPINE (449)
QUETIAPINE (299)
CARBIDOPA\LEVODOPA (248)
HALOPERIDOL (216)
DIAZEPAM (185)
CLONAZEPAM (179)
LORAZEPAM (165)
Which APIXABAN Alternatives Have Lower Salivary hypersecretion Risk?
APIXABAN vs APOMORPHINE
APIXABAN vs APRACLONIDINE
APIXABAN vs APREMILAST
APIXABAN vs APREPITANT
APIXABAN vs APROTININ